Oral Proteins and Peptides Market (4th Edition) by Target Disease Indication (acromegaly, celiac disease, chronic idiopathic constipation, enteric hyperoxaluria, inflammatory bowel disease and type II diabetes), Type of Molecule (protein and peptide), Technology Platforms, Biological Target (GC-C, insulin receptor, oxalate and others), Mechanism of Action (receptor stimulation, substrate degradation and others), Key Players, and Key Geographical Regions (North America, Europe, Asia-Pacific and RoW), 2022-2032

  • Lowest Price Guaranteed From USD 5,899

  • Published
    February 2022

  • Pages
    421

  • View Count
    15456

Example Insights

Oral-Protein-and-Peptide-Therapeutics-Market-Context Oral-Protein-and-Peptide-Therapeutics-Market-Development-Pipeline Oral-Protein-and-Peptide-Therapeutics-Market-Distribution-by-Status-of-Development Oral-Protein-and-Peptide-Therapeutics-Market-Competitiveness-Analysis
Oral-Protein-and-Peptide-Therapeutics-Market-Clinical-Trial-Analysis Oral-Protein-and-Peptide-Therapeutics-Market-Key-Opinion-Leaders Oral-Protein-and-Peptide-Therapeutics-Market-Publication-Analysis Oral-Protein-and-Peptide-Therapeutics-Market-Year-wise-Distribution
Oral-Protein-and-Peptide-Therapeutics-Market-Market-Landscape Oral-Protein-and-Peptide-Therapeutics-Market-Platform-Competitiveness Oral-Protein-and-Peptide-Therapeutics-Market-Patent-nalysis Oral-Protein-and-Peptide-Therapeutics-Market-Big-Pharma-Initiatives
Oral-Protein-and-Peptide-Therapeutics-Market-Funding-and-Investments Oral-Protein-and-Peptide-Therapeutics-Market-Commercialization-Strategies Oral-Protein-and-Peptide-Therapeutics-Market-Distribution-by-Target-of-Platform Oral-Protein-and-Peptide-Therapeutics-Market-Distribution-by-Geography

Overview

The field of oral proteins / peptides has enormous opportunities. I believe the field will continue to grow at a rapid pace considering the healthy clinical pipeline of oral proteins / peptides.

-Chief Executive Officer, US based small-sized developer

Since the approval of the first protein / peptide-based therapy (recombinant human insulin) in 1982, there has been a substantial increase in the R&D initiatives focused on such products. Earlier, majority of the biologics were administered subcutaneously. However, with the technological advancements in delivery formulations, oral delivery of therapeutic interventions   has gained significant traction, prompting stakeholders to leverage their expertise in the development of orally administrable proteins / peptides. Interestingly, in the last decade, three orally administered protein / peptide-based therapies have been approved, namely Mycapssa® (2020), Trulance® (2017) and Linzess® (2012) across different geographies. The rising popularity of this upcoming class of therapeutics has led to the reformulation / development of oral protein / peptide-based product candidates for the treatment of a myriad of disease indications across multiple therapeutic areas (including but not limited to metabolic disorders, gastrointestinal disorders, autoimmune disorders). It is worth mentioning that oral administration is a favorable route for delivery of drugs to pediatric and geriatric patients, primarily due to its non-invasive nature. In addition, the ease of administration  associated with the oral delivery method has been demonstrated increase treatment adherence  to as well as reduce the risk of non-compliance.

Protein / peptide-based therapeutics have revolutionized the pharmaceutical landscape, this can be attributed to the wide applications and target specific nature of such interventions. However, oral formulations of protein / peptide-based drugs have been associated with several drawbacks, including poor bioavailability and drug decomposition in the gastrointestinal tract. In order to mitigate the aforementioned challenges, players engaged in this domain have conducted extensive research for the development of novel biological targets, thereby, strengthening their research pipelines. In addition, this segment of the industry has also attracted the attention of both private and public sector investors / investment funds, which have extended financial support to the initiatives of developers. It is also worth mentioning that, over the last few years, the market has witnessed an active participation of big pharma players and substantial partnership activity. Given the ongoing research and development initiatives and an encouraging response to the already marketed drugs, the oral protein / peptide therapies market is poised to witness significant growth over the coming decade.

Scope of the Report

The ‘Oral Proteins and Peptides Market (4th Edition) by Target Disease Indication (acromegaly, celiac disease, chronic idiopathic constipation, enteric hyperoxaluria, inflammatory bowel disease and type II diabetes), Type of Molecule (protein and peptide), Technology Platforms, Biological Target (GC-C, insulin receptor, oxalate and others), Mechanism of Action (receptor stimulation, substrate degradation and others), Key Players,  and Key Geographical Regions (North America, Europe, Asia-Pacific and RoW), 2022-2032’ report provides an extensive study on the current market landscape of orally administrable protein / peptide-based therapeutics, along with the future market potential. In addition, it provides an in-depth analysis, highlighting the market landscape of technology providers engaged in this domain. Amongst other elements, the report features:

  • A detailed assessment of the current market landscape of oral proteins / peptides, providing information on the developer, type of molecule (protein or peptide), phase of development (commercial, clinical, preclinical or discovery stage), target therapeutic area(s), biological target, mechanism of action, number of amino acids and affiliated technology platform. In addition, the chapter includes information on drug developer(s), highlighting their year of establishment, company size, and location of headquarters.
  • A detailed competitiveness analysis of oral protein / peptide therapy developers based on several relevant parameters, such as supplier power (in terms of years of experience and employee count), pipeline strength and phase of development.
  • An in-depth analysis of the product pipeline and developer companies, featuring three schematic representations; these include [A] a four dimensional grid analysis, representing the distribution of oral proteins / peptides (on the basis of the type of molecule) across various target therapeutic areas and stages of development, [B] a logo landscape of companies involved in the development of oral protein / peptide-based drugs, distributed on the basis of phase of development of pipeline candidates and size of developer companies (small, mid-sized and large companies), and [C] a schematic world map representation, highlighting the most active geographies, in terms of the presence of various industry players engaged in the development of oral proteins / peptides.
  • A detailed analysis identifying the key opinion leaders (KOLs), featuring a 2X2 analysis to assess the relative experience of certain KOLs, who were shortlisted based on their contributions (in terms of involvement in various clinical studies) in this field.
  • An overview of the current market landscape of technology platforms available for the development of oral protein / peptide therapeutics, along with information on their developer, type of platform, compatible API types, target therapeutic area, dosage form and status of development of products. In addition, the chapter includes information on technology developer(s), highlighting their year of their establishment, company size and location of headquarters.
  • A 2X2 matrix, comparing product competitiveness and supplier power of the technology platforms that are presently being used for the development of oral proteins / peptides. The analysis takes into consideration several parameters, such as year of establishment, company size and development activity (number of drugs in both preclinical / clinical stages of development).
  • An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, by companies that are engaged in this field.
  • An analysis of the partnerships that have been established in the domain, over the last five years, covering licensing agreements, acquisitions, R&D agreements, product commercialization agreements, clinical trial agreements and other relevant deals.
  • A detailed review of more than 300 peer-reviewed, scientific articles related to research on oral protein / peptides, which have been published since 2017. 
  • A detailed analysis of completed, ongoing and planned clinical studies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial status, trial phase, type of sponsor / collaborator, patient segment, target therapeutic area, study design, most active players (industry and non-industry) and regional distribution of trials.
  • An in-depth analysis of the patents related to oral protein / peptides, filed / granted since 2017, based on several relevant parameters, such as publication year, geographical location / patent jurisdiction, legal status, CPC symbols, emerging focus areas, type of applicant and leading players (by number of patents). In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.
  • An analysis of big pharma players engaged in this domain, featuring a spider-web analysis based on several relevant parameters, such as number of pipeline candidates, partnership agreements and publications.
  • A detailed case study on protein / peptide contract manufacturing, featuring a list of over 140 CMOs that are currently offering contract manufacturing services for such products / product candidates.
  • An elaborate discussion on the various commercialization and lifecycle management strategies that have been adopted by drug developers engaged in this domain across different stages of therapy development, including prior to drug launch, at / during drug launch and post-marketing stage.
  • A discussion on affiliated trends, key drivers and challenges, under a SWOT framework. The analysis features a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall oral proteins / peptides market.

One of the key objectives of this study was to understand the primary growth drivers and estimate the future size of the market based on various parameters, such as target consumer segments, likely adoption rates and expected pricing. We have also provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2022-2032. In addition, we have provided the likely distribution of the market based on [A] target disease indication (acromegaly, celiac disease, chronic idiopathic constipation, enteric hyperoxaluria, inflammatory bowel disease and type II diabetes), [B] type of molecule (protein and peptide), [C] technology platforms, [D] biological target (GC-C, insulin receptor, oxalate, others), [E] mechanism of action (receptor stimulation, substrate degradation and others) [F] key players, and [G] key geographical regions (North America, Europe, Asia-Pacific and RoW). In order to account for the uncertainties associated with the growth of the oral proteins / peptides market and to add robustness to our model, we have provided three forecast scenarios, portraying conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The study includes detailed transcripts of discussions held with Dinesh Srinivasan (Director, Anthera Pharmaceuticals), Stig K Hansen (Co-founder and CEO, Carmot Therapeutics), Terry Dyck (CEO, IGY Life Sciences and Technology) and Richard Franklin (CEO, Constant Therapeutics). 

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the key players involved in the development of oral protein / peptide therapeutics?
  • Which technologies are leveraged the most by oral protein / peptide therapy developers?
  • Who are the key opinion leaders in this domain?
  • Which geographies are the most active in conducting clinical trials focused on oral protein / peptide therapeutics?
  • Which companies have received the maximum funding for the development for oral protein / peptide therapeutics? Who are the most prominent investors?
  • Which partnership models are commonly adopted by industry stakeholders in the development of oral protein / peptide therapeutics? 
  • Which organizations have filed the maximum number of patents in this field?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of key insights captured in our research. It offers a high-level view on the current state of oral protein / peptide therapeutics market and its likely evolution in the short to mid-term, and long term.

Chapter 3 provides a comparison of the key characteristics of small molecules and large molecules / biologics. In addition, it includes a detailed discussion on proteins / peptides, highlighting their potential as therapeutic agents. Further, it features a discussion on the various routes of administration used for the delivery of drugs, with special focus on oral route. The chapter elaborates on the likely advantages and challenges associated with the oral route of administration. In addition, it includes a comprehensive discussion on the various approaches developed / under development for the effective oral delivery of proteins / peptides.

Chapter 4 includes information on over 125 programs for oral protein / peptide therapeutics that are either approved or being developed across different stages (commercial, clinical, preclinical or discovery stage) for the treatment of various indications. It features a comprehensive analysis of pipeline molecules, based on the type of molecule (protein or peptide), phase of development (commercial, clinical, preclinical or discovery stage), target therapeutic area(s), biological target, mechanism of action, number of amino acids and affiliated technology platform. In addition, the chapter includes information on drug developer(s), highlighting their year of establishment, company size, and location of headquarters.

Chapter 5 provides a detailed competitiveness analysis of oral protein / peptide therapy developers based on several relevant parameters, such as supplier power (in terms of years of experience and employee count), pipeline strength and phase of development.

Chapter 6 presents the key insights derived from the study. It features an in-depth analysis of the product pipeline and developer companies, featuring three schematic representations; these include [A] a four dimensional grid analysis, representing the distribution of oral proteins / peptides (on the basis of the type of molecule) across various target therapeutic areas and stages of development, [B] a logo landscape of companies involved in the development of oral protein / peptide-based drugs, distributed on the basis of phase of development of pipeline candidates and size of developer companies (small, mid-sized and large companies), and [C] a schematic world map representation, highlighting the most active geographies, in terms of the presence of various industry players engaged in the development of oral proteins / peptides

Chapter 7 provides a detailed analysis identifying the key opinion leaders (KOLs), featuring a 2X2 analysis to assess the relative experience of certain KOLs who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field.

Chapter 8 highlights the potential target indications (segregated by therapeutic areas) that are currently the prime focus of companies developing oral proteins / peptides. These include metabolic disorders, gastrointestinal disorders and autoimmune disorders. The chapter also provides details on disease epidemiology, available diagnostic tests, and currently available treatment options for each indication and their likely side effects.

Chapter 9 contains detailed profiles of drugs that are either marketed or are in late stage (phase II / III and above) of development. Each profile features an overview of the drug, history of development, mechanism of action, dosage information (if available), manufacturing information (if available), current status of development, clinical trial information, key clinical trial results, historical sales (if marketed) and information on the developer.

Chapter 10 provides a review of oral proteins / peptides belonging other drug classes, namely cyclic peptides and PERTs, which are either commercialized or still under development. The chapter features detailed profiles of three popular orally administrable, therapeutic proteins / peptides (Minirin®, Sandimmune® and Sollpura®), which were discovered before 2000. Each profile contains an overview of the drug, history of development, chemical structure and mechanism of action, dosage information (if marketed), clinical trial information (if the product is currently under development), patent portfolio (if available) and information on the other commercially available treatment options for the disease indications for which each drug is approved.

Chapter 11 provides an overview of the market landscape of technology platforms available for the development of oral protein/ peptide therapeutics, including an analysis based on parameters, such as type of platform (drug formulation, drug development), compatible API types (peptide, protein and others), target therapeutics area, dosage form and status of development of products. In addition, the chapter also includes an analysis on the companies developing these platforms, based on year of their establishment, company size, and location of headquarters.

Chapter 12 features a 2X2 matrix, comparing product competitiveness and supplier power of the oral drug delivery technology platforms that are presently being utilized for the generation of oral proteins / peptides. The analysis takes into consideration several parameters, such as year of establishment, company size and development activity (number of drugs in both preclinical / clinical stages of development).

Chapter 13 features detailed profiles of some of the key technologies that have been used to develop oral protein / peptide therapeutics. Each profile contains details on the technology, including mechanism of action, pipeline molecules developed using the technology, its advantages and the various partnerships that were established related to the technology.

Chapter 14 presents details on various investments received by companies that are engaged in the development of oral protein / peptide therapeutics and / or associated delivery technologies. It also includes detailed analysis of the funding instances, based on several parameters, such as number of instances, amount invested, type of funding, focus aera, area of application, target therapeutic area, most active players and geographical analysis.

Chapter 15 provides a detailed analysis of the recent collaborations established since 2017. It includes analysis based on relevant parameters, such as year of partnership, type of agreement, focus area, type of partner and regional distribution of partnerships.

Chapter 16 presents a detailed review of more than 300 peer-reviewed, scientific articles related to research on oral protein / peptides, which have been published since 2017, including analysis based on parameters, such as year of publication, key focus area, type of molecule, popular keywords, key journals (in terms of number of articles published in this domain and impact factor of the journal) and affiliations.

Chapter 17 presents a detailed analysis of completed, ongoing and planned clinical studies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial status, trial phase, type of sponsor / collaborator, patient segment, target therapeutic area, study design, most active players (industry and non-industry) and regional distribution of trials.

Chapter 18 provides an in-depth analysis of the patents related to oral protein / peptides, filed / granted since 2017, based on several relevant parameters, such as publication year, geographical location / patent jurisdiction, legal status, CPC symbols, emerging focus areas, type of applicant and leading players (by number of patents). In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.

Chapter 19 presents an analysis of big pharma players engaged in this domain, featuring a spider-web analysis based on several relevant parameters, such as number of pipeline candidates, partnership agreements and publications.

Chapter 20 presents an insightful market forecast analysis, highlighting the likely growth of oral protein / peptide therapeutics market, till 2032. In order to provide a detailed future outlook, our projections have been segmented across [A] target disease indication (acromegaly, celiac disease, chronic idiopathic constipation, enteric hyperoxaluria, inflammatory bowel disease and type II diabetes), [B] type of molecule (protein and peptide), [C] technology platforms, [D] biological target (GC-C, insulin receptor, oxalate, others), [E] mechanism of action (receptor stimulation, substrate degradation and others) [F] key players, and [G] key geographical regions (North America, Europe, Asia-Pacific and RoW).

Chapter 21 features a case study on the role of CMOs in the field of oral proteins / peptides. It provides details on the various factors that need to be considered while selecting the right CMO partner for the pharmaceutical companies. In addition, it includes a list of over 140 contract manufacturers that claim to have the necessary capabilities for protein / peptide manufacturing.

Chapter 22 provides an elaborate discussion on the various commercialization and lifecycle management strategies that have been adopted by drug developers engaged in this domain across different stages of therapy development, including prior to drug launch, at / during drug launch and post-marketing stage.

Chapter 23 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of the oral proteins / peptides market, under a comprehensive SWOT framework. The chapter also features a schematic Harvey ball analysis to highlight the relative impact of each SWOT parameter on the overall oral proteins / peptides market.

Chapter 24 summarizes the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the oral protein / peptide therapeutics market.

Chapter 25 is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with Dinesh Srinivasan (Director, Anthera Pharmaceuticals), Stig K Hansen (Co-founder and CEO, Carmot Therapeutics), Terry Dyck (CEO, IGY Life Sciences and Technology) and Richard Franklin (CEO, Constant Therapeutics).

Chapter 26 is an appendix, which provides tabulated information on the historical developments.

Chapter 27 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 28 is an appendix, which contains a list of companies and organizations.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY
2.1. Chapter Overview

3. INTRODUCTION
3.1. Chapter Overview
3.2. Comparison of Biologics and Small Molecules
3.3. Introduction to Proteins
3.3.1. Protein Structure
3.3.2. Classification of Proteins
3.4. Introduction to Peptides
3.4.1. Peptide Structure
3.4.2. Classification of Peptides
3.4.2.1. Synthetic Peptides
3.4.2.2. Recombinant Peptides

3.5. Routes of Administration for Proteins / Peptides
3.5.1. Parenteral Administration
3.5.1.1. Intramuscular Route
3.5.1.2. Intravenous Route
3.5.1.3. Subcutaneous Route

3.5.2. Non-Parenteral Administration
3.5.2.1. Buccal / Sublingual Route
3.5.2.2. Intranasal Route
3.5.2.3. Oral Route
3.5.2.4. Ocular Route
3.5.2.5. Pulmonary Route / Inhalation
3.5.2.6. Rectal Route
3.5.2.7. Transdermal Route
3.5.3. Comparison of Different Routes of Drug Administration

3.6. Oral Delivery of Proteins / Peptides
3.6.1. Key Advantages of Oral Administration
3.6.2. Key Challenges Associated with Oral Administration

3.7. Approaches Used for Structural and Bioavailability Enhancement
3.7.1. Absorption Enhancers
3.7.2. Chemical Modification
3.7.2.1 Pro Drug Approach
3.7.3. Enzyme Inhibitors
3.7.4. Muco-Adhesive Polymeric Systems
3.7.5. Nanoparticular Delivery Systems
3.7.5.1. Liposomes
3.7.5.2. Nanoparticles / Microparticles
3.7.6. PEGylation

3.8. Concluding Remarks

4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Oral Proteins / Peptide Therapeutics: Market Landscape
4.2.1. Analysis by Type of Molecule
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Target Therapeutic Area
4.2.4. Analysis by Biological Target
4.2.5. Analysis by Mechanism of Action
4.2.6. Analysis by Phase of Development and Mechanism of Action
4.2.7. Analysis by Number of Amino Acids
4.2.8. Key Drug Development Platforms: Analysis by Number of Products

4.3. Oral Proteins / Peptide Therapeutics: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Company Size and Location of Headquarters
4.3.5. Most Active Players: Analysis by Number of Pipeline Candidates

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Key Assumptions and Parameters
5.3. Oral Protein / Peptide Therapy Developers: Competitiveness Analysis

6. KEY INSIGHTS
6.1. Chapter Overview
6.2. Oral Proteins / Peptides Pipeline: Grid Analysis
6.3. Oral Proteins / Peptides Pipeline: Developer Landscape
6.4. Oral Proteins / Peptides Pipeline: Regional Landscape (Industry Players)

7. KOL ANALYSIS
7.1. Chapter Overview
7.2. Oral Protein / Peptide Therapeutics: List of Key Opinion Leaders
7.2.1. Analysis by Type of Current Organization
7.2.2. Analysis by Geography
7.2.2.1. Analysis by Region (Continent-wise)
7.2.2.2. Analysis by Region (Country-wise)
7.2.3. Analysis by Number of Investigators and Current Organization
7.2.4. Analysis by Qualification of KOL
7.2.5. Comparison of KOL Activeness v/s Strength (Scatter Plot)
7.2.6. Comparison of Roots Analysis Score v/s Third Party Score
7.2.7. Prominent Players: Comparison of Roots Analysis Score v/s Third Party Score
7.2.8. Most Active Key Opinion Leaders: Comparison of Professional Network v/s Academic Strength

8. KEY THERAPEUTIC AREAS
8.1. Chapter Overview
8.2. Metabolic Disorders
8.2.1. Diabetes
8.2.1.1. Disease Description
8.2.1.2. Associated Health Risks / Complications
8.2.1.3. Epidemiology
8.2.1.4. Disease Diagnosis
8.2.1.5. Current Treatment Options
8.2.1.5.1. Insulin Therapies
8.2.1.5.2. Non-Insulin Therapies
8.2.1.6. Side Effects of Current Treatment Options
8.2.1.7. Oral Proteins / Peptides for Diabetes

8.2.2. Obesity
8.2.2.1. Disease Description
8.2.2.2. Epidemiology
8.2.2.3. Current Treatment Options
8.2.2.4. Side Effects of Current Treatment Options
8.2.2.5. Oral Proteins / Peptides for Obesity

8.2.3. Non-alcoholic Steatohepatitis (NASH)
8.2.3.1. Disease Description
8.2.3.2. Epidemiology
8.2.3.3. Current Treatment Options
8.2.3.4. Oral Proteins / Peptides for NASH

8.3. Digestive and Gastrointestinal Disorders
8.3.1. Ulcerative Colitis
8.3.1.1. Disease Description
8.3.1.2. Epidemiology
8.3.1.3. Current Treatment Options
8.3.1.4. Side Effects of Current Treatment Options
8.3.1.5. Oral Proteins / Peptides for Ulcerative Colitis

8.3.2. Crohn’s Disease
8.3.2.1. Disease Description
8.3.2.2. Epidemiology
8.3.2.3. Current Treatment Options
8.3.2.4. Side Effects of Current Treatment Options
8.3.2.5. Oral Proteins / Peptides for Crohn’s Disease

8.4. Infectious Diseases
8.4.1. C. difficile Infections (CDIs)
8.4.1.1. Disease Description
8.4.1.2. Epidemiology
8.4.1.3. Disease Diagnosis
8.4.1.4. Current Treatment Options
8.4.1.5. Side Effects of Current Treatment Options
8.4.1.6. Oral Proteins / Peptides for CDIs

8.5. Autoimmune Disorders
8.5.1. Celiac Disease
8.5.1.1. Disease Description
8.5.1.2. Epidemiology
8.5.1.3. Disease Diagnosis
8.5.1.4. Current Treatment Options
8.5.1.5. Oral Proteins / Peptides for Celiac Disease

8.6. Hormonal Disorders
8.6.1. Acromegaly
8.6.1.1. Disease Description
8.6.1.2. Epidemiology
8.6.1.3. Disease Diagnosis
8.6.1.4. Current Treatment Options
8.6.1.5. Side Effects of Current Treatment Options
8.6.1.6. Oral Proteins / Peptides for Acromegaly

8.7. Bone Disorders
8.7.1. Osteoporosis
8.7.1.1. Disease Description
8.7.1.2. Epidemiology
8.7.1.3. Disease Diagnosis
8.7.1.4. Current Treatment Options
8.7.1.5. Side Effects of Current Treatment Options
8.7.1.6. Oral Proteins / Peptides for Osteoporosis

9. MARKETED AND LATE-STAGE DRUG PROFILES
9.1. Chapter Overview
9.2. Linzess® / Constella® / Linaclotide (Ironwood Pharmaceuticals)
9.2.1. Drug Overview
9.2.2. History of Development
9.2.3. Mechanism of Action
9.2.4. Dosage Form, Treatment Regimen and Price
9.2.5. Manufacturing Information
9.2.6. Current Status of Development
9.2.7. Clinical Studies
9.2.8. Key Clinical Trial Results
9.2.9. Historical Sales
9.2.10. Developer Overview

9.3. Trulance® / Plecanatide (Synergy Pharmaceuticals)
9.3.1. Drug Overview
9.3.2. History of Development
9.3.3. Mechanism of Action
9.3.4. Dosage Form, Treatment Regimen and Price
9.3.5. Manufacturing Information
9.3.6. Current Status of Development
9.3.7. Clinical Studies
9.3.8. Key Clinical Trial Results
9.3.9. Historical Sales
9.3.10. Developer Overview

9.4. TBRIA™ / Oral Calcitonin (Tarsa Therapeutics / Enteris BioPharma)
9.4.1. Drug Overview
9.4.2. History of Development
9.4.3. Mechanism of Action
9.4.4. Manufacturing Information
9.4.5. Current Status of Development
9.4.6. Clinical Studies
9.4.7. Key Clinical Trial Results
9.4.8. Developer Overview

9.5. Mycapssa® / (Chiasma Pharma)
9.5.1. Drug Overview
9.5.2. History of Development
9.5.3. Mechanism of Action
9.5.4. Manufacturing Information
9.5.5. Current Status of Development
9.5.6. Clinical Studies
9.5.7. Key Clinical Trial Results
9.5.8. Developer Overview

9.6. ALLN-177 (Allena Pharmaceuticals)
9.7. INN-202 (9 Meters Biopharma)
9.8. ORMD-0801 (Oramed Pharmaceuticals)
9.9. IN-105 (Biocon)
9.10. Oral HDV Insulin (Diasome Pharmaceuticals)

10. CASE STUDIES: MINIRIN®, SANDIMMUNE® AND SOLLPURA®
10.1. Chapter Overview
10.2. Minirin® / DDAVP (Ferring Pharmaceuticals)
10.2.1. Drug Overview
10.2.2. History of Development
10.2.3. Chemical Structure and Mechanism of Action
10.2.4. Dosage Form, Treatment Regimen and Price
10.2.5. Patent Portfolio
10.2.6. Competitive Landscape

10.3. Sandimmune® / Neoral® (Novartis)
10.3.1. Drug Overview
10.3.2. History of Development
10.3.3. Mechanism of Action
10.3.4. Dosage Form, Treatment Regimen and Price
10.3.5. Patent Portfolio
10.3.6. Competitive Landscape

10.4. Sollpura® / Liprotamase (Anthera Pharmaceuticals)
10.4.1. Drug Overview
10.4.2. History of Development
10.4.3. Chemical Structure and Mechanism of Action
10.4.4. Current Status of Development
10.4.5. Clinical Studies
10.4.6. Competitive Landscape

11. ORAL PROTEIN / PEPTIDE DEVELOPMENT TECHNOLOGIES: MARKET LANDSCAPE
11.1. Chapter Overview
11.2. Oral Protein / Peptide Development Technologies: Market Landscape
11.2.1. Analysis by Type of Technology
11.2.2. Analysis by Compatible API Types
11.2.3. Analysis by Target Therapeutic Area
11.2.4. Analysis by Dosage Form
11.2.5. Analysis by Status of Development of Products

11.3. Oral Protein / Peptide Development Technologies: Developer Landscape
11.3.1 Analysis by Year of Establishment
11.3.2. Analysis by Company Size
11.3.3 Analysis by Location of Headquarters
11.3.4. Analysis by Company Size and Location of Headquarters

12. PRODUCT COMPETITIVENESS ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Product Competitiveness Analysis: Key Technologies

13. ORAL DRUG DELIVERY TECHNOLOGY PLATFORMS
13.1. Chapter Overview
13.2. Oral Drug Delivery: List of Technology Platforms

13.3. Technology Profiles
13.3.1. Axcess™ Oral Drug Delivery Technology (Proxima Concepts)
13.3.1.1. Developer Overview
13.3.1.2. Technology Overview
13.3.1.3. Drug Delivery Mechanism
13.3.1.4. Key Advantages
13.3.1.5. Oral Proteins / Peptides Pipeline
13.3.1.6. Collaborations

13.3.2. Eligen™ Technology (Emisphere Technologies)
13.3.2.1. Developer Overview
13.3.2.2. Technology Overview
13.3.2.3. Drug Delivery Mechanism
13.3.2.4. Key Advantages
13.3.2.5. Oral Proteins / Peptides Pipeline
13.3.2.6. Collaborations

13.3.3. Entera Technology (Entera Bio)
13.3.3.1. Developer Overview
13.3.3.2. Technology Overview
13.3.3.3. Drug Delivery Mechanism
13.3.3.4. Key Advantages
13.3.3.5. Oral Proteins / Peptides Pipeline

13.3.4. NTRA Oral Delivery Technology (Nutrinia)
13.3.4.1. Developer Overview
13.3.4.2. Technology Overview
13.3.4.3. Drug Delivery Mechanism
13.3.4.4. Key Advantages
13.3.4.5. Oral Proteins / Peptides Pipeline

13.3.5. Peptelligence® Technology (Enteris BioPharma)
13.3.5.1. Developer Overview
13.3.5.2. Technology Overview
13.3.5.3. Drug Delivery Mechanism
13.3.5.4. Key Advantages
13.3.5.5. Oral Proteins / Peptides Pipeline
13.3.5.6. Collaborations

13.3.6. Protein Oral Delivery (POD™) Technology (Oramed Pharmaceuticals)
13.3.6.1. Developer Overview
13.3.6.2. Technology Overview
13.3.6.3. Drug Delivery Mechanism
13.3.6.4. Key Advantages
13.3.6.5. Oral Proteins / Peptides Pipeline

13.3.7. Transient Permeability Enhancer (TPE®) Technology (Chiasma Pharma)
13.3.7.1. Developer Overview
13.3.7.2. Technology Overview
13.3.7.3. Drug Delivery Mechanism
13.3.7.4. Key Advantages
13.3.7.5. Oral Proteins / Peptides Pipeline

13.3.8. Uroguanylin Analogue Technology (Synergy Pharmaceuticals)
13.3.8.1. Developer Overview
13.3.8.2. Technology Overview
13.3.8.3. Drug Delivery Mechanism
13.3.8.4. Key Advantages
13.3.8.5. Oral Proteins / Peptides Pipeline

14. FUNDING AND INVESTMENT ANALYSIS
14.1. Chapter Overview
14.2. Types of Funding
14.3. Oral Proteins / Peptides: Funding and Investment Analysis
14.3.1. Analysis by Cumulative Number of Funding Instances
14.3.2. Analysis by Cumulative Amount Invested
14.3.3. Analysis by Type of Funding
14.3.4. Analysis by Year, Type of Funding and Amount Invested
14.3.5. Analysis by Focus Area
14.3.6. Analysis by Area of Application
14.3.7. Analysis by Target Therapeutic Area
14.3.8. Analysis by Geography
14.3.9. Most Active Players: Analysis by Number of Instances
14.3.10. Most Active Players: Analysis by Amount Invested
14.4. Concluding Remarks

15. RECENT COLLABORATIONS
15.1. Chapter Overview
15.2. Partnership Models
15.3. Oral Proteins / Peptides: Partnerships and Collaborations
15.3.1. Analysis by Year of Partnership
15.3.2. Analysis by Type of Partnership
15.3.3. Analysis by Area of Application
15.3.4. Analysis by Type of Partner
15.3.5. Analysis by Focus Area
15.3.6. Analysis by Target Therapeutic Area
15.3.7. Most Active Players: Analysis by Number of Partnerships
15.3.8. Analysis by Geography
15.3.9. Intercontinental and Intracontinental Agreements

16. PUBLICATION ANALYSIS
16.1. Chapter Overview
16.2. Oral Proteins / Peptides: List of Publications
16.2.1. Analysis by Year of Publication
16.2.2. Analysis by Type of Molecule
16.2.3. Analysis by Target Therapeutic Area
16.2.4. Word Cloud of Study Titles
16.2.5. Most Prominent Journals: Analysis by Number of Publications
16.2.6. Most Prominent Authors: Analysis by Number of Publications

17. CLINICAL TRIAL ANALYSIS
17.1. Chapter Overview
17.2. Scope and Methodology
17.3. Oral Protein / Peptide Therapeutics: Clinical Trial Analysis
17.3.1. Analysis by Trial Registration Year
17.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
17.3.3. Analysis by Trial Status
17.3.4. Analysis by Trial Phase
17.3.5. Analysis by Trial Registration Year and Trial Status
17.3.6. Analysis by Enrolled Patient Population and Trial Phase
17.3.7. Analysis by Type of Sponsor / Collaborator
17.3.8. Analysis by Patient Segment
17.3.9. Analysis by Target Therapeutic Area
17.3.10. Analysis by Study Design
17.3.11. Most Active Players: Analysis by Number of Registered Trials
17.3.12. Analysis by Number of Trials and Geographical Location
17.3.13. Analysis by Number of Trials, Trial Status and Geographical Location
17.3.14. Analysis by Enrolled Patient Population and Trial Status

18. PATENT ANALYSIS
18.1. Chapter Overview
18.2. Scope and Methodology
18.3. Oral Protein / Peptide Therapeutics: Patent Analysis
18.3.1. Analysis by Publication Year
18.3.2. Analysis by Patent Jurisdiction
18.3.3. Analysis by Legal Status
18.3.4. Analysis by CPC Symbols
18.3.5. Emerging Focus Areas
18.3.6. Analysis by Type of Applicant
18.3.7. Leading Players: Analysis by Number of Patents
18.3.8. Key Inventors: Analysis by Number of Patents

18.4. Oral Protein / Peptide Therapeutics: Patent Benchmarking Analysis
18.4.1. Analysis by Patent Characteristics
18.4.2. Analysis by Geography
18.5. Oral Protein / Peptide Therapeutics: Patent Valuation Analysis

19. BIG PHARMA ANALYSIS
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Oral Protein / Peptide Therapeutics: Big Pharma Initiatives
19.3.1. Analysis by Target Therapeutic Area
19.3.2. Analysis by Type of Initiative
19.3.3. Big Pharma Players: Benchmarking Analysis

20. MARKET FORECAST AND OPPORTUNITY ANALYSIS
20.1. Chapter Overview
20.2. Scope and Limitations
20.3. Forecast Methodology
20.4. Global Oral Protein / Peptide Therapy Market, 2022-2032
20.4.1. Oral Protein / Peptide Therapy Market: Distribution by Target Disease Indication
20.4.2. Oral Protein / Peptide Therapy Market: Distribution by Type of Molecule
20.4.3. Oral Protein / Peptide Therapy Market: Distribution by Technology Platform
20.4.4. Oral Protein / Peptide Therapy Market: Distribution by Biological Target
20.4.5. Oral Protein / Peptide Therapy Market: Distribution by Mechanism of Action
20.4.6. Oral Protein / Peptide Therapy Market: Distribution by Key Players
20.4.7. Oral Protein / Peptide Therapy Market: Distribution by Geography

20.5. Oral Proteins / Peptides Market: Product-wise Sales Forecasts
20.5.1. Linzess® / Constella® / Linaclotide (Ironwood Pharmaceuticals)
20.5.1.1. Target Patient Population
20.5.1.2. Sales Forecast

20.5.2. Trulance® / Plecanatide (Synergy Pharmaceuticals)
20.5.2.1. Target Patient Population
20.5.2.2. Sales Forecast

20.5.3. Mycapssa® / Octreolin (Chiasma Pharma)
20.5.3.1. Target Patient Population
20.5.3.2. Sales Forecast

20.5.4. ALLN-177 (Allena Pharmaceuticals)
20.5.4.1. Target Patient Population
20.5.4.2. Sales Forecast

20.5.5. Larazotide INN-202 (Innovate Biopharmaceuticals)
20.5.5.1. Target Patient Population
20.5.5.2. Sales Forecast

20.5.6. Oral HDV Insulin (Diasome Pharmaceuticals)
20.5.6.1. Target Patient Population
20.5.6.2. Sales Forecast

20.5.7. ORMD-0801 (Oramed Pharmaceuticals)
20.5.7.1. Target Patient Population
20.5.7.2. Sales Forecast

20.5.8. IN-105 / Insulin Tregopil (Biocon)
20.5.8.1. Target Patient Population
20.5.8.2. Sales Forecast

21. CASE STUDY: PROTEIN / PEPTIDE MANUFACTURING
21.1. Chapter Overview
21.2. Key Steps Involved in Protein / Peptide Manufacturing
21.3. Challenges Associated with Protein / Peptide Manufacturing
21.4. Current Scenario of Protein / Peptide Manufacturing
21.5. Growing Demand for Contract Manufacturing
21.5.1. Selecting A Suitable CMO Partner

21.5.2. Protein / Peptide CMOs: Market Landscape
21.5.2.1. Analysis by Year of Establishment
21.5.2.2. Analysis by Company Size
21.5.2.3. Analysis by Location of Headquarters

22. KEY COMMERCIALIZATION / LIFECYCLE MANAGEMENT STRATEGIES
22.1. Successful Drug Launch Strategy: ROOTS Framework
22.2. Successful Drug Launch Strategy: Product Differentiation
22.3. Commonly Adopted Commercialization Strategies based on the Development Stage of the Product
22.4. Key Commercialization / Lifecycle Management Strategies Adopted by Companies Focused on Oral Protein / Peptide Therapeutics
22.4.1. Strategies Adopted Before Therapy Approval

22.5. Strategies Adopted During / Post Therapy Approval
22.6. Analysis by Ease of Implementation, Value Addition and Current Adoption (Harvey Ball Framework)

23. SWOT ANALYSIS
23.1. Chapter Overview
23.2. Comparison of SWOT Factors

24. CONCLUSION
24.1 Chapter Overview

25. EXECUTIVE INSIGHTS
25.1. Chapter Overview

25.2. Anthera Pharmaceuticals
25.2.1. Company Snapshot
25.2.2. Interview Transcript: Dinesh Srinivasan, Director

25.3. Carmot Therapeutics
25.3.1. Company Snapshot
25.3.2. Interview Transcript: Stig K Hansen, CEO

25.4. IGY Life Sciences and Technology
25.4.1. Company Snapshot
25.4.2. Interview Transcript: Terry Dyck, President and CEO

25.5. Constant Therapeutics
25.5.1. Company Snapshot
25.5.2. Interview Transcript: Richard Franklin, CEO

26. APPENDIX 1: RECENT DEVELOPMENTS

27. APPENDIX 2: TABULATED DATA

28. APPENDIX 3: LIST OF COMPANIES

List Of Figures

Figure 2.1 Executive Summary: Pipeline Overview
Figure 2.2 Executive Summary: KOL Analysis
Figure 2.3 Executive Summary: Drug Development Technology Providers Landscape
Figure 2.4 Executive Summary: Funding and Investment Analysis
Figure 2.5 Executive Summary: Partnerships and Collaborations
Figure 2.6 Executive Summary: Publication Analysis
Figure 2.7 Executive Summary: Clinical Trial Analysis
Figure 2.8 Executive Summary: Patent Analysis
Figure 2.9 Executive Summary: Big Pharma Analysis
Figure 2.10 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Comparison of Key Characteristics of Biologics and Small Molecules
Figure 3.2 Classification of Proteins
Figure 3.3 Routes of Administration for Proteins / Peptides
Figure 3.4 Drug Delivery: Distribution by Route of Administration
Figure 3.5 Mechanisms of Drug Transport through the Intestinal Epithelium
Figure 3.6 Mechanisms of Drug Transport through the Intestinal Epithelium via Attachment of Absorption Enhancers
Figure 3.7 Mechanisms of Drug Transport through the Intestinal Epithelium via Pro Drug Approach
Figure 3.8 Mechanisms of Drug Transport through the Intestinal Epithelium via Attachment of Enzyme Inhibitors
Figure 4.1 Oral Protein / Peptide Therapeutics: Distribution by Type of Molecule
Figure 4.2 Oral Protein / Peptide Therapeutics: Distribution by Phase of Development
Figure 4.3 Oral Protein / Peptide Therapeutics: Distribution by Target Therapeutic Area
Figure 4.4 Oral Protein / Peptide Therapeutics: Distribution by Biological Target
Figure 4.5 Oral Protein / Peptide Therapeutics: Distribution by Mechanism of Action
Figure 4.6 Oral Protein / Peptide Therapeutics: Distribution by Phase of Development and Mechanism of Action
Figure 4.7 Oral Protein / Peptide Therapeutics: Distribution by Number of Amino Acids
Figure 4.8 Key Drug Development Platforms: Distribution by Number of Products
Figure 4.9 Oral Protein / Peptide Therapeutics Developers: Distribution by Year of Establishment
Figure 4.10 Oral Protein / Peptide Therapeutics Developers: Distribution by Company Size
Figure 4.11 Oral Protein / Peptide Therapeutics Developers: Distribution by Location of Headquarters (Region-wise)
Figure 4.12 Oral Protein / Peptide Therapeutics Developers: Distribution by Location of Headquarters (Country-wise)
Figure 4.13 Oral Protein / Peptide Therapeutics Developers: Distribution by Company Size and Location of Headquarters (Region-wise)
Figure 4.14 Most Active Players: Distribution by Number of Pipeline Candidates
Figure 4.15 Most Active Players: Distribution by Phase of Development
Figure 5.1 Oral Protein / Peptide Therapy Developers: Competitiveness Analysis
Figure 6.1 Oral Proteins / Peptides: Distribution by Therapeutic Area, Type of Molecule and Phase of Development (Grid Analysis)
Figure 6.2 Oral Proteins / Peptides Developer Landscape: Distribution by Company Size and Phase of Development
Figure 6.3 Oral Proteins / Peptides Regional Landscape (Industry Players): Distribution by Location of Headquarters and Pipeline Strength
Figure 7.1 KOL Analysis: Distribution by Type of Current Organization
Figure 7.2 KOL Analysis: Distribution by Geography
Figure 7.3 KOL Analysis: Distribution by Region (Continent-wise)
Figure 7.4 KOL Analysis: Distribution by Region (Country-wise)
Figure 7.5 KOL Analysis: Distribution by Number of Investigators and Current Organization
Figure 7.6 KOL Analysis: Distribution by Qualification of KOL
Figure 7.7 Comparison of KOL Activeness v/s Strength (Scatter Plot)
Figure 7.8 Comparison of Roots Analysis Score v/s Third Party Score
Figure 7.9 Prominent Players: Comparison of Roots Analysis Score v/s Third Party Score
Figure 7.10 Most Active Key Opinion Leaders: Comparison of Professional Network v/s Academic Strength
Figure 8.1 Diabetes: Diagnostic Limits for Plasma Glucose Levels
Figure 8.2 Non-Insulin Therapies for Diabetes
Figure 9.1 Linzess®: History of Development
Figure 9.2 Linzess®: Historical Sales, 2015-2020 (USD Million)
Figure 9.3 Trulance®: History of Development
Figure 9.4 TBRIA®: History of Development
Figure 9.5 Mycapssa®: History of Development
Figure 11.1 Oral Protein / Peptide Development Technologies: Distribution by Type of Technology
Figure 11.2 Oral Protein / Peptide Development Technologies: Distribution by Compatible API Types
Figure 11.3 Oral Protein / Peptide Development Technologies: Distribution by Type of Technology and Compatible API Types
Figure 11.4 Oral Protein / Peptide Development Technologies: Distribution by Target Therapeutic Area
Figure 11.5 Oral Protein / Peptide Development Technologies: Distribution by Dosage Form
Figure 11.6 Oral Protein / Peptide Development Technologies: Distribution by Status of Development of Products
Figure 11.7 Oral Protein / Peptide Development Technology Developers: Distribution by Year of Establishment
Figure 11.8 Oral Protein / Peptide Development Technology Developers: Distribution by Company Size
Figure 11.9 Oral Protein / Peptide Development Technology Developers: Distribution by Location of Headquarters (Region-wise)
Figure 11.10 Oral Protein / Peptide Development Technology Developers: Distribution by Location of Headquarters (Country-wise)
Figure 11.11 Oral Protein / Peptide Development Technology Developers: Distribution by Company Size and Location of Headquarters (Region-wise)
Figure 12.1 Oral Protein / Peptide Development Technologies: Competitiveness Analysis
Figure 14.1 Funding and Investment Analysis: Cumulative Distribution by Number of Funding Instances
Figure 14.2 Funding and Investment Analysis: Cumulative Amount Invested (USD Million)
Figure 14.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 14.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 14.5 Funding and Investment Analysis: Summary of Amount Invested
Figure 14.6 Funding and Investment Analysis: Distribution by Year, Type of Funding and Amount Invested (USD Million)
Figure 14.7 Funding and Investment Analysis: Distribution of Amount Invested by Focus Area (USD Million)
Figure 14.8 Funding and Investment Analysis: Distribution of Amount Invested by Area of Application (USD Million)
Figure 14.9 Funding and Investment Analysis: Distribution of Number of Instances by Target Therapeutic Area
Figure 14.10 Funding and Investment Analysis: Distribution of Amount Invested by Target Therapeutic Area (USD Million)
Figure 14.11 Funding and Investment Analysis: Regional Distribution of Funding Instances
Figure 14.12 Funding and Investment Analysis: Regional Distribution by Total Amount Invested (USD Million)
Figure 14.13 Most Active Players: Distribution by Number of Instances
Figure 14.14 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 14.15 Funding and Investment Analysis: Concluding Remarks
Figure 15.1 Partnerships and Collaborations: Cumulative Year-wise Distribution
Figure 15.2 Partnerships and Collaborations: Distribution by Type of Agreement
Figure 15.3 Partnerships and Collaborations: Distribution by Area of Application
Figure 15.4 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Agreement
Figure 15.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 15.6 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 15.7 Partnerships and Collaborations: Distribution by Focus Area
Figure 15.8 Partnerships and Collaborations: Distribution by Target Therapeutic Area
Figure 15.9 Most Active Players: Distribution by Number of Partnerships
Figure 15.10 Partnerships and Collaborations: Geographical Distribution
Figure 15.11 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 16.1 Publication Analysis: Cumulative Year-wise Trend
Figure 16.2 Publication Analysis: Distribution by Type of Molecule
Figure 16.3 Publication Analysis: Distribution by Target Therapeutic Area
Figure 16.4 Publication Analysis: Word Cloud of Study Titles
Figure 16.5 Most Prominent Journals: Distribution by Number of Publications
Figure 16.6 Most Prominent Authors: Distribution by Number of Publications
Figure 17.1 Clinical Trial Analysis: Methodology
Figure 17.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
Figure 17.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Figure 17.4 Clinical Trial Analysis: Distribution by Trial Status
Figure 17.5 Clinical Trial Analysis: Distribution by Trial Phase
Figure 17.6 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 17.7 Clinical Trial Analysis: Distribution by Enrolled Patient Population and Trial Phase
Figure 17.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 17.9 Clinical Trial Analysis: Distribution by Patient Segment
Figure 17.10 Clinical Trial Analysis: Distribution by Target Therapeutic Area
Figure 17.11 Clinical Trial Analysis: Distribution by Study Design
Figure 17.12 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 17.13 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 17.14 Clinical Trial Analysis: Distribution by Number of Registered Trials and Geographical Location
Figure 17.15 Clinical Trial Analysis: Distribution by Number of Registered Trials, Trial Status and Geographical Location
Figure 17.16 Clinical Trial Analysis: Distribution by Enrolled Patient Population and Trial Status
Figure 18.1 Patent Analysis: Distribution by Type of Patent
Figure 18.2 Patent Analysis: Cumulative Distribution by Publication Year
Figure 18.3 Patent Analysis: Distribution by Patent Jurisdiction
Figure 18.4 Patent Analysis: Distribution by Legal Status
Figure 18.5 Patent Analysis: Distribution by CPC Symbols
Figure 18.6 Patent Analysis: Emerging Focus Areas
Figure 18.7 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization
Figure 18.8 Leading Industry Players: Distribution by Number of Patents
Figure 18.9 Leading Non-Industry Players: Distribution by Number of Patents
Figure 18.10 Leading Industry Players: Distribution by International Patents
Figure 18.11 Leading Patent Assignees: Distribution by Number of Patents
Figure 18.12 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Symbols)
Figure 18.13 Patent Analysis: Distribution of Patents by Age
Figure 18.14 Oral Protein / Peptide Therapeutics: Patent Valuation
Figure 19.1 Big Pharma Players: Heat Map Analysis of Top Pharmaceutical Companies
Figure 19.2 Big Pharma Players: Benchmarking Analysis
Figure 20.1 Global Oral Protein / Peptide Therapy Market, 2022-2032 (USD Million)
Figure 20.2 Oral Protein / Peptide Therapy Market: Distribution by Target Disease Indication, 2022, 2025 and 2032 (USD Million)
Figure 20.3 Oral Proteins / Peptide Therapy Market: Distribution by Type of Molecule, 2022, 2025 and 2032 (USD Million)
Figure 20.4 Oral Proteins / Peptide Therapy Market: Distribution by Technology Platform, 2022, 2025 and 2032 (USD Million)
Figure 20.5 Oral Proteins / Peptide Therapy Market: Distribution by Biological Target, 2022, 2025 and 2032 (USD Million)
Figure 20.6 Oral Proteins / Peptide Therapy Market: Distribution by Mechanism of Action, 2022, 2025 and 2032 (USD Million)
Figure 20.7 Oral Proteins / Peptide Therapy Market: Distribution by Key Players, 2022, 2025 and 2032 (USD Million)
Figure 20.8 Oral Protein / Peptide Therapy Market: Distribution by Geography 2022 and 2032 (USD Million)
Figure 20.9 Linzess® (Ironwood Pharmaceuticals): Estimated Sales, 2022-2032 (USD Million)
Figure 20.10 Trulance® (Bausch Health Sciences): Estimated Sales, 2022-2032 (USD Million)
Figure 20.11 Mycapssa® (Chiasma): Estimated Sales, 2022-2032 (USD Million)
Figure 20.12 ALLN-177 (Allena Pharmaceuticals): Estimated Sales, 2022-2032 (USD Million)
Figure 20.13 INN-202 (9 Meters Biopharma): Estimated Sales, 2022-2032 (USD Million)
Figure 20.14 Oral HDV Insulin (Diasome Pharmaceuticals): Estimated Sales, 2022-2032 (USD Million)
Figure 20.15 ORMD-0801 (Oramed Pharmaceuticals): Estimated Sales, 2022-2032 (USD Million)
Figure 20.16 IN-105 (Biocon): Estimated Sales, 2022-2032 (USD Million)
Figure 21.1 Key Steps Involved in the Manufacturing of Biologics
Figure 21.2 Approval Trend for Small Molecule and Large Molecule Drugs (2005-2017)
Figure 21.3 Factors for Selecting a CMO Partner
Figure 21.4 Protein / Peptide Manufacturers: Distribution by Year of Establishment
Figure 21.5 Protein / Peptide Manufacturers: Distribution by Company Size
Figure 21.6 Protein / Peptide Manufacturers: Distribution by Location of Headquarters
Figure 22.1 Key Commercialization Strategies: Harvey Ball Analysis
Figure 22.2 Successful Drug Launch Strategy: ROOTS Framework
Figure 22.3 Successful Drug Launch Strategy: Product Differentiation
Figure 22.4 Commonly Adopted Commercialization Strategies based on Development Stage of the Product
Figure 22.5 Harvey Ball Analysis: Commercialization Strategies Adopted by Oral Protein / Peptide Therapy Developers
Figure 23.1 Oral Proteins / Peptides SWOT Analysis: Overview
Figure 23.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 24.1 Concluding Remarks: Pipeline Overview
Figure 24.2 Concluding Remarks: KOL Analysis
Figure 24.3 Concluding Remarks: Drug Development Technology Providers Landscape
Figure 24.4 Concluding Remarks: Funding and Investment Analysis
Figure 24.5 Concluding Remarks: Partnerships and Collaborations
Figure 24.6 Concluding Remarks: Publication Analysis
Figure 24.7 Concluding Remarks: Clinical Trial Analysis
Figure 24.8 Concluding Remarks: Patent Analysis
Figure 24.9 Concluding Remarks: Big Pharma Analysis
Figure 24.10 Concluding Remarks: Market Forecast and Opportunity Analysis

List Of Tables

Table 3.1 Comparison of Key Routes of Delivery
Table 4.1 Oral Proteins / Peptide Therapeutics: Drug Pipeline
Table 4.2 Oral Proteins / Peptide Therapeutics: Information on Disease Indication, Target Therapeutic Area, Biological Target and Mechanism of Action
Table 4.3 Oral Proteins / Peptide Therapeutics: Information on Number of Amino Acids and Platform Used for Development
Table 4.4 Oral Proteins / Peptide Therapy Developers: Information on Year of Establishment, Employee Count, Company Size and Headquarters
Table 4.5 Oral Proteins / Peptide Therapeutics: Other Drugs
Table 7.1 Oral Proteins / Peptide Therapeutics: Principal Investigators
Table 8.1 Diabetes: Current Treatment Options
Table 8.2 Diabetes: Side Effects of Current Treatment Options
Table 8.3 Diabetes: Oral Proteins / Peptides Pipeline
Table 8.4 Obesity: Side Effects of Current Treatment Options
Table 8.5 Obesity: Oral Proteins / Peptides Pipeline
Table 8.6 NASH: Oral Proteins / Peptides Pipeline
Table 8.7 Ulcerative Colitis: Current Treatment Options
Table 8.8 Ulcerative Colitis: Side Effects of Current Treatment Options
Table 8.9 Ulcerative Colitis: Oral Proteins / Peptides Pipeline
Table 8.10 Crohn’s Disease: Current Treatment Options
Table 8.11 Crohn’s Disease: Side Effects of Current Treatment Options
Table 8.12 Crohn’s Disease: Oral Proteins / Peptides Pipeline
Table 8.13 CDIs: Diagnostic Testing
Table 8.14 CDIs: Severity Scoring System and Treatment Options
Table 8.15 CDIs: Side Effects of Current Treatment Options
Table 8.16 CDIs: Oral Proteins / Peptides Pipeline
Table 8.17 Celiac Disease: Oral Proteins / Peptides Pipeline
Table 8.18 Acromegaly: Current Treatment Options
Table 8.19 Acromegaly: Side Effects of Current Treatment Options
Table 8.20 Acromegaly: Oral Proteins / Peptides Pipeline
Table 8.21 Osteoporosis: Current Treatment Options
Table 8.22 Osteoporosis: Side Effects of Current Treatment Options
Table 8.23 Osteoporosis: Oral Proteins / Peptides Pipeline
Table 9.1 Oral Peptides / Proteins: List of Drugs Profiled
Table 9.2 Linzess®: Dosage Details
Table 9.3 Linzess®: Current Status of Development
Table 9.4 Linzess®: Clinical Trials
Table 9.5 Linzess®: Results of Phase III Clinical Trial for CIC
Table 9.6 Ironwood Pharmaceuticals: Key Highlights
Table 9.7 Trulance®: Current Status of Development
Table 9.8 Trulance®: Clinical Trials
Table 9.9 Salix Pharmaceuticals: Key Highlights
Table 9.10 TBRIA™: Current Status of Development
Table 9.11 TBRIA™: Clinical Trials
Table 9.12 TBRIA™: Results of Phase III ORACAL Clinical Trial
Table 9.13 Tarsa Therapeutics: Key Highlights
Table 9.14 Mycapssa®: Current Status of Development
Table 9.15 Mycapssa®: Clinical Trials
Table 9.16 Mycapssa®: Results of Phase III Clinical Trial for Acromegaly
Table 9.17 Chiasma Pharma: Key Highlights
Table 9.18 Drug Profile: ALLN-177
Table 9.19 Drug Profile: INN-202
Table 9.20 Drug Profile: ORMD-0801
Table 9.21 Drug Profile: IN-105
Table 9.22 Drug Profile: Oral HDV Insulin
Table 10.1 Oral Proteins / Peptides: List of Other Associated Drugs
Table 10.2 Minirin®: Generic Versions
Table 10.3 Minirin®: Dosage Details
Table 10.4 Minirin®: Price of Tablets
Table 10.5 Minirin®: Patent Portfolio
Table 10.6 Minirin®: Competitive Landscape
Table 10.7 Sandimmune® / Neoral®: Generic Versions
Table 10.8 Sandimmune® / Neoral®: Dosage Details
Table 10.9 Neoral®: Patent Portfolio
Table 10.10 Sandimmune® / Neoral®: Competitive Landscape
Table 10.11 Sollpura®: Mechanism of Action
Table 10.12 Sollpura®: Current Status of Development
Table 10.13 Sollpura®: Clinical Trials
Table 10.14 Sollpura®: Current Treatment Options
Table 11.1 Oral Protein / Peptide Therapy Development Technologies: Information on Type of Technology, Compatible API Types, Number of Development Programs
Table 11.2 Oral Protein / Peptide Therapy Development Technologies: Information on Target Therapeutic Area and Dosage Form
Table 11.3 Oral Protein / Peptide Therapy Development Technology Developers: Information on Year of Establishment, Employee Count, Company Size and Headquarters
Table 13.1 Oral Delivery Technology Platforms: Comparison of Key Features
Table 13.2 Oral Delivery Technology Platforms: Clinical Stages of Development
Table 13.3 Axcess™ Technology: Oral Proteins / Peptides Pipeline
Table 13.4 Eligen™ Technology: Oral Proteins / Peptides Pipeline
Table 13.5 Entera Technology: Oral Proteins / Peptides Pipeline
Table 13.6 NTRA Oral Delivery Technology: Oral Proteins / Peptides Pipeline
Table 13.7 Peptelligence® Technology: Oral Proteins / Peptides Pipeline
Table 13.8 POD™ Technology: Oral Proteins / Peptides Pipeline
Table 13.9 TPE® Technology: Oral Proteins / Peptides Pipeline
Table 13.10 Uroguanylin Analogue Platform: Oral Proteins / Peptides Pipeline
Table 14.1 Oral Proteins / Peptides: Funding and Investment Analysis
Table 14.2 Oral Proteins / Peptides: Summary of Investments
Table 15.1 Oral Proteins / Peptides: Recent Partnerships
Table 16.1 Oral Proteins / Peptides: List of Publications
Table 18.1 Patent Analysis: CPC Symbols
Table 18.2 Patent Analysis: Most Popular CPC Symbols
Table 18.3 Patent Analysis: List of Top 10 CPC Symbols
Table 18.4 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 18.5 Patent Analysis: List of Relatively Higher Value Patents
Table 20.1 Oral Proteins / Peptides Market: Potential Candidates
Table 20.2 Oral Proteins / Peptides Forecast Assumptions: Price Estimation in Key Geographies
Table 20.3 Oral Proteins / Peptides Forecast Assumptions: Growth Rate Estimation by Key Indications
Table 20.4 Linzess®: Target Patient Population
Table 20.5 Trulance®: Target Patient Population
Table 20.6 Mycapssa®: Target Patient Population
Table 20.7 ALLN-177: Target Patient Population
Table 20.8 Larazotide INN-202: Target Patient Population
Table 20.9 Oral HDV Insulin: Target Patient Population
Table 20.10 ORMD-0801: Target Patient Population
Table 20.11 IN-105: Target Patient Population
Table 21.1 List of Contract Manufacturers Involved in Proteins / Peptides Manufacturing
Table 22.1 Oral Protein / Peptide Therapeutics: Key Commercialization / Lifecycle Management Strategies
Table 25.1 Anthera Pharmaceuticals: Key Highlights
Table 25.2 Carmot Therapeutics: Key Highlights
Table 25.3 IGY Life Sciences and Technology: Key Highlights
Table 25.4 Constant Therapeutics: Key Highlights
Table 26.1 Oral Protein / Peptide Therapeutics: Distribution by Type of Molecule
Table 26.2 Oral Protein / Peptide Therapeutics: Distribution by Phase of Development
Table 26.3 Oral Protein / Peptide Therapeutics: Distribution by Target Therapeutic Area
Table 26.4 Oral Protein / Peptide Therapeutics: Distribution by Biological Target
Table 26.5 Oral Protein / Peptide Therapeutics: Distribution by Mechanism of Action
Table 26.6 Oral Protein / Peptide Therapeutics: Distribution by Phase of Development and Mechanism of Action
Table 26.7 Oral Protein / Peptide Therapeutics: Distribution by Number of Amino Acids
Table 26.8 Key Drug Development Platforms: Distribution by Number of Products
Table 26.9 Oral Protein / Peptide Therapeutics Developers: Distribution by Year of Establishment
Table 26.10 Oral Protein / Peptide Therapeutics Developers: Distribution by Company Size
Table 26.11 Oral Protein / Peptide Therapeutics Developers: Distribution by Location of Headquarters (Region-wise)
Table 26.12 Oral Protein / Peptide Therapeutics Developers: Distribution by Location of Headquarters (Country-wise)
Table 26.13 Oral Protein / Peptide Therapeutics Developers: Distribution by Company Size and Location of Headquarters (Region-wise)
Table 26.14 Most Active Players: Distribution by Number of Pipeline Candidates
Table 26.15 Most Active Players: Distribution by Phase of Development
Table 26.16 KOL Analysis: Distribution by Type of Current Organization
Table 26.17 KOL Analysis: Distribution by Geography
Table 26.18 Linzess®: Historical Sales, 2015-2020 (USD Million)
Table 26.19 Oral Protein / Peptide Development Technologies: Distribution by Type of Technology
Table 26.20 Oral Protein / Peptide Development Technologies: Distribution by Compatible API Types
Table 26.21 Oral Protein / Peptide Development Technologies: Distribution by Target Therapeutic Area
Table 26.22 Oral Protein / Peptide Development Technology Developers: Distribution by Year of Establishment
Table 26.23 Oral Protein / Peptide Development Technology Developers: Distribution by Company Size
Table 26.24 Oral Protein / Peptide Development Technology Developers: Distribution by Location of Headquarters (Region-wise)
Table 26.25 Oral Protein / Peptide Development Technology Developers: Distribution by Location of Headquarters (Country-wise)
Table 26.26 Oral Protein / Peptide Development Technologies: Competitiveness Analysis
Table 26.27 Funding and Investment Analysis: Cumulative Distribution by Number of Funding Instances
Table 26.28 Funding and Investment Analysis: Cumulative Amount Invested (USD Million)
Table 26.29 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Table 26.30 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Table 26.31 Funding and Investment Analysis: Summary of Amount Invested
Table 26.32 Funding and Investment Analysis: Distribution by Year, Type of Funding and Amount Invested (USD Million)
Table 26.33 Funding and Investment Analysis: Distribution of Amount Invested by Focus Area (USD Million)
Table 26.34 Funding and Investment Analysis: Distribution of Amount Invested by Area of Application (USD Million)
Table 26.35 Funding and Investment Analysis: Distribution of Number of Instances by Target Therapeutic Area
Table 26.36 Funding and Investment Analysis: Distribution of Amount Invested by Target Therapeutic Area (USD Million)
Table 26.37 Funding and Investment Analysis: Regional Distribution of Funding Instances
Table 26.38 Funding and Investment Analysis: Regional Distribution by Total Amount Invested (USD Million)
Table 26.39 Most Active Players: Distribution by Number of Instances
Table 26.40 Most Active Players: Distribution by Amount Invested (USD Million)
Table 26.41 Partnerships and Collaborations: Cumulative Year-wise Distribution
Table 26.42 Partnerships and Collaborations: Distribution by Type of Agreement
Table 26.43 Partnerships and Collaborations: Distribution by Area of Application
Table 26.44 Partnerships and Collaborations: Distribution by Type of Partner
Table 26.45 Partnerships and Collaborations: Distribution by Focus Area
Table 26.46 Partnerships and Collaborations: Distribution by Target Therapeutic Area
Table 26.47 Most Active Players: Distribution by Number of Partnerships
Table 26.48 Partnerships and Collaborations: Geographical Distribution
Table 26.49 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 26.50 Publication Analysis: Cumulative Year-wise Trend
Table 26.51 Publication Analysis: Distribution by Type of Molecule
Table 26.52 Publication Analysis: Distribution by Target Therapeutic Area
Table 26.53 Most Prominent Journals: Distribution by Number of Publications
Table 26.54 Most Prominent Authors: Distribution by Number of Publications
Table 26.55 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
Table 26.56 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient population
Table 26.57 Clinical Trial Analysis: Distribution by Trial Status
Table 26.58 Clinical Trial Analysis: Distribution by Trial Phase
Table 26.59 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 26.60 Clinical Trial Analysis: Distribution by Enrolled Patient Population and Trial Phase
Table 26.61 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 26.62 Clinical Trial Analysis: Distribution by Patient Segment
Table 26.63 Clinical Trial Analysis: Distribution by Target Therapeutic Area
Table 26.64 Clinical Trial Analysis: Distribution by Study Design
Table 26.65 Most Active Industry Players: Distribution by Number of Registered Trials
Table 26.66 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 26.67 Clinical Trial Analysis: Distribution by Number of Registered Trials and Geographical Location
Table 26.68 Clinical Trial Analysis: Distribution by Number of Registered Trials, Trial Status and Geographical Location
Table 26.69 Clinical Trial Analysis: Distribution by Enrolled Patient Population, Trial Status
Table 26.70 Patent Analysis: Distribution by Type of Patent
Table 26.71 Patent Analysis: Cumulative Distribution by Publication Year
Table 26.72 Patent Analysis: Distribution by Patent Jurisdiction
Table 26.73 Patent Analysis: Distribution by Legal Status
Table 26.74 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization
Table 26.75 Leading Industry Players: Distribution by Number of Patents
Table 26.76 Leading Non-Industry Players: Distribution by Number of Patents
Table 26.77 Leading Industry Players: Distribution by International Patents
Table 26.78 Leading Patent Assignees: Distribution by Number of Patents
Table 26.79 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Symbols)
Table 26.80 Patent Analysis: Distribution of Patents by Age
Table 26.81 Oral Protein / Peptide Therapeutics: Patent Valuation
Table 26.82 Overall Oral Proteins / Peptide Therapy Market, 2022-2032, Conservative, Base and Optimistic Scenario (USD Million)
Table 26.83 Oral Proteins / Peptide Therapy Market: Distribution by Target Disease Indication, 2022, 2025 and 2032, Conservative, Base and Optimistic Scenario (USD Million)
Table 26.84 Oral Proteins / Peptide Therapy Market: Distribution by Type of Molecule, 2022, 2025 and 2032, Conservative, Base and Optimistic Scenario (USD Million)
Table 26.85 Oral Proteins / Peptide Therapy Market: Distribution by Technology Platforms, 2022, 2025 and 2032, Conservative, Base and Optimistic Scenario (USD Million)
Table 26.86 Oral Proteins / Peptide Therapy Market: Distribution by Biological Target, 2022, 2025 and 2032, Conservative, Base and Optimistic Scenario (USD Million)
Table 26.87 Oral Proteins / Peptide Therapy Market: Distribution by Mechanism of Action, 2022, 2025 and 2032, Conservative, Base and Optimistic Scenario (USD Million)
Table 26.88 Oral Proteins / Peptide Therapy Market: Distribution by Key Players, 2022, 2025 and 2032, Conservative, Base and Optimistic Scenario (USD Million)
Table 26.89 Oral Proteins / Peptide Therapy Market: Distribution by Geography 2022 and 2032, Conservative, Base and Optimistic Scenario (USD Million)
Table 26.90 Linzess® (Ironwood Pharmaceuticals): Estimated Sales, 2022-2032 (USD Million)
Table 26.91 Trulance® (Bausch Health Sciences): Estimated Sales, 2022-2032 (USD Million)
Table 26.92 Mycapssa® (Chiasma): Estimated Sales, 2022-2032 (USD Million)
Table 26.93 ALLN-177 (Allena Pharmaceuticals): Estimated Sales, 2022-2032 (USD Million)
Table 26.94 INN-202 (9 Meters Biopharma): Estimated Sales, 2022-2032 (USD Million)
Table 26.95 Oral HDV Insulin (Diasome Pharmaceuticals): Estimated Sales, 2022-2032 (USD Million)
Table 26.96 ORMD-0801 (Oramed Pharmaceuticals): Estimated Sales, 2022-2032 (USD Million)
Table 26.97 IN-105 (Biocon): Estimated Sales, 2022-2032 (USD Million)
Table 26.98 Approval Trend for Small Molecule and Large Molecule Drugs (2005-2020)
Table 26.99 Factors for Selecting a CMO Partner
Table 26.100 Protein / Peptide Manufacturers: Distribution by Year of Establishment
Table 26.101 Protein / Peptide Manufacturers: Distribution by Company Size
Table 26.102 Protein / Peptide Manufacturers: Distribution by Location of Headquarters

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 3P Biopharmaceuticals
  2. 7-Med Health Ventures 
  3. 9 Meters Biopharma
  4. Aalto Scientific
  5. Abbott Laboratories
  6. AbbVie 
  7. Abeona Therapeutics
  8. Abingworth
  9. ABL Venture Capital
  10. Abzena
  11. Access Pharmaceuticals
  12. ACES Pharma
  13. Acorn Biomedical 
  14. ActoGeniX 
  15. Adage Capital Management
  16. Adams Capital Management
  17. Adar Biotech
  18. Adcock Ingram
  19. Aegis Capital
  20. Aescap Venture
  21. Affilogic
  22. Affinity Life Sciences
  23. AIM ImmunoTech
  24. AIMM Therapeutics
  25. Ajinomoto Bio-Pharma Services
  26. Alaven Pharmaceutical 
  27. Alba Therapeutics
  28. Albert Einstein Medical Center
  29. Albiochem
  30. Albireo Pharma
  31. Alcami
  32. Alchemia
  33. Aldevron
  34. Allena Pharmaceuticals
  35. Allergan
  36. Almac
  37. Almirall
  38. Alnara Pharmaceuticals 
  39. Alphabet
  40. Alrov
  41. Alta Biopharma Partners
  42. Althea Technologies
  43. Altus Pharmaceuticals
  44. Alza Pharmaceuticals
  45. Amarillo Biosciences
  46. Amatsigroup
  47. AmatsiQBiologicals
  48. AmbioPharm
  49. Amerant Bancorp
  50. Amgen
  51. Anaheim Clinical Trials
  52. AnaSpec
  53. Anthera Pharmaceuticals
  54. Aphios
  55. Apotex
  56. Applied Molecular Transport
  57. Aptalis Pharma
  58. Aquestive Therapeutics
  59. Aravis Ventures
  60. ARCH Venture Partners
  61. Arena Pharmaceuticals
  62. Arisaph Pharmaceuticals
  63. ArisGen 
  64. Armenian Development Agency
  65. Asahi Glass
  66. Ascendia Pharmaceuticals
  67. Ascent Biomedical Ventures
  68. Aspen Oss
  69. Assaf Harofeh Medical Center
  70. Assembly Biosciences
  71. Astellas Pharma
  72. AstraZeneca
  73. Asymchem
  74. Atara Technology Ventures
  75. Atlantic Peptides
  76. Atrix Laboratories
  77. Augusta University
  78. AURA Biotechnologies
  79. Aurigene Pharmaceutical Services
  80. Auspep
  81. Austin Chemical
  82. AutekBio
  83. Avaxia Biologics
  84. Avid Bioservices
  85. Avista Development
  86. Axcan Pharma 
  87. AzurRx BioPharma
  88. Baccinex 
  89. Bachem
  90. Baekeland Funds
  91. BAM Biotech
  92. Barr Pharmaceuticals
  93. Basque Regional Government
  94. Batavia Biosciences
  95. Bausch Health
  96. Baxter BioPharma Solutions
  97. Bayer
  98. BCN Peptides
  99. Beacon Angels
  100. BeiGene
  101. Beijing Friendship Hospital
  102. Beijing Tiantan Hospital
  103. Beijing Tongren Hospital 
  104. Bessemer Venture Partners
  105. Beta Fund
  106. Bharat Serums and Vaccines
  107. Bill & Melinda Gates Foundation
  108. BIND Therapeutics
  109. BINEX
  110. Bio Elpida
  111. Bio Farma
  112. Biocell
  113. Biocon
  114. BioConnection
  115. Biodel 
  116. BioEconomy Capital
  117. Biogen
  118. Bio-Kinetic Clinical Applications
  119. Biolaxy
  120. BioLingus
  121. Biological Process Development Facility (BPDF)
  122. Biomatik
  123. Biomay
  124. Biomedical Advanced Research and Development Authority (BARDA)
  125. Biopeptek Pharmaceuticals
  126. BioPharmaceuticals Australia
  127. Biosynergy
  128. Bio-Synthesis
  129. Biotech Fund Flanders
  130. BioTechLogic
  131. Biotechnology and Biological Sciences Research Council
  132. Biotechpharma
  133. Bio-Thera Solutions
  134. BioVectra
  135. BioVeda Capital
  136. Biovest
  137. Biovian
  138. Black Beret Life Sciences
  139. Blue Devil Trust
  140. Boehringer Ingelheim
  141. Bone Medical 
  142. Bossa Ventures
  143. Boston Harbor Angels
  144. Botanix Pharmaceuticals
  145. Brigham and Women's Hospital
  146. Broadview Ventures
  147. Brown University
  148. Bumi Medic
  149. Burrard Pharmaceuticals
  150. Butler Hospital
  151. Buttonwood Financial 
  152. BVF Partners
  153. BZ Bank
  154. Cadila Healthcare 
  155. Calvert Research Institute
  156. Canaan Partners
  157. Canada Armenia Trading House
  158. Cancer Care Northwest
  159. Cancer Specialists of South Texas
  160. Cara Therapeutics
  161. CARBOGEN AMCIS
  162. CARB-X
  163. Cardinal Health 
  164. Carmot Therapeutics
  165. Catalent
  166. Cathay Ventures
  167. CBL
  168. Cedars-Sinai Medical Center
  169. Celiac Disease Foundation
  170. Cell Culture Company
  171. Cell Culture Company (C3)
  172. Celltrion
  173. Celltrion Healthcare
  174. Celonic
  175. CEM
  176. Center for Biocatalysis and Bioprocessing (CBB)
  177. Century Pharmaceuticals
  178. Cerbios-Pharma
  179. Changhai Hospital 
  180. Changzheng Hospital 
  181. Chao Family Comprehensive Cancer Center
  182. Charles River Laboratories
  183. Chattem
  184. CHEMI
  185. ChemPartner
  186. Cherrystone Angels
  187. Chiasma
  188. Chicago Innovation Fund
  189. Chiesi Farmaceutici
  190. Children's Reserach Institute
  191. ChinaTech Peptide
  192. Chinese Peptide Company
  193. Chinese PLA General Hospital
  194. Chong Kun Dang Pharmaceutical 
  195. Circle33
  196. Citizens Bank
  197. ClinSearch
  198. CNF Investments
  199. CNR Institute of Clinical Physiology
  200. Cobra Biologics
  201. Columbia University
  202. Connecticut Innovations
  203. Constant Therapeutics
  204. CordenPharma
  205. CoreMed 
  206. Cosmo Pharmaceuticals
  207. Courtagen Life Sciences
  208. CPC Scientific
  209. Creative Peptides
  210. CreoSalus
  211. CRG
  212. Crystal Horizon Investments
  213. CSBio
  214. CureDM
  215. Curia
  216. Cystic Fibrosis Foundation Therapeutics
  217. CytoPharm
  218. Cytovance Biologics
  219. D.N.A Biomedical Solutions
  220. Dalton Pharma Services
  221. Dana-Farber Cancer Institute
  222. Danish Megatrend Invest
  223. Devon Park BioVentures
  224. Diabetology
  225. Diapin Therapeutics
  226. Diasome Pharmaceuticals
  227. Digestive Care 
  228. DM Bio
  229. Docor International
  230. Dr. Falk Pharma
  231. Duke University
  232. Edward P. Bass Group
  233. EirGenix
  234. Elasmogen
  235. Eli Lilly
  236. Elite Research Institute
  237. Embio
  238. Emergent BioSolutions
  239. Emisphere Technologies
  240. Emory University
  241. Encap Drug Delivery
  242. Encorium Group
  243. enGene
  244. Engineered BioPharmaceuticals 
  245. Engineering and Physical Sciences Research Council
  246. Entera Bio
  247. Enteris BioPharma
  248. Enterome Bioscience
  249. Entrega
  250. Enzene Biosciences
  251. EPQ
  252. Esperante Ventures
  253. Eti Karle Clinical
  254. EuBiologics
  255. EUCODIS Bioscience
  256. Eurogentec
  257. Europe Pharmaceutical
  258. European Biomedical Research Institute of Salerno (EBRIS)
  259. European Commission
  260. European Cystic Fibrosis Society 
  261. European Medical Association
  262. Evonik Industries
  263. F2 Capital
  264. F3 Ventures
  265. Ferrer Internacional
  266. Ferring Pharmaceuticals
  267. Fidelity Management & Research Company
  268. FightMND
  269. Firebird Global Master Fund
  270. First Affiliated Hospital of Harbin Medical University
  271. Fondazione Centro San Raffaele del Monte Tabor
  272. Forbion Capital Partners
  273. Foresite Capital
  274. Forest Laboratories
  275. Founders Fund
  276. Frazier Healthcare Partners
  277. French Innovative Leukemia Organisation
  278. FUJIFILM Diosynth Biotechnologies
  279. Gala Biotech
  280. Galera Therapeutics
  281. GD Searle
  282. GE Healthcare
  283. General Hospital of Shenyang Military Region 
  284. Generex Biotechnology
  285. GeneScience Pharmaceuticals
  286. GenIbet Biopharmaceuticals
  287. Genta
  288. GF Ventures
  289. GGV Capital
  290. Gila Therapeutics
  291. Gilead Sciences
  292. Gimv
  293. GlaxoSmithKline
  294. Glycotope Biotechnology
  295. Golden Seeds
  296. Goodwin Biotechnology
  297. GP Pharm
  298. Grand River Aseptic Manufacturing
  299. Granite State Angels
  300. Great Point Partners
  301. Grupo Espanol de Tumores Neuroendocrinos
  302. GTP Technology
  303. Guangzhou Medical University
  304. Gülhane Military Medical School
  305. GV
  306. H.I.G. BioHealth Partners
  307. Hadassah Medical Center
  308. HALIX 
  309. Harvard Business School Angels 
  310. Hayashibara Biochemical Laboratories 
  311. HBG Beteiligungs- und Beratungsgesellschaft
  312. HBM BioCapital
  313. Health Biotech
  314. Healthcare Royalty Partners
  315. Hefei Tianhui Incubator of Technologies
  316. Hemispherx Biopharma
  317. Hepasome Pharmaceuticals
  318. Heptares Therapeutics
  319. Hetero Drugs
  320. Highbridge Capital
  321. High-Tech Gründerfonds
  322. Hoechst Marion Roussel
  323. Hong Kong Institute of Biotechnology
  324. Horizons Ventures
  325. Hovione
  326. Hybio Pharmaceutical
  327. iBio
  328. IDT Biologika
  329. IGY Life Sciences and Technology
  330. Immuron
  331. InCube Ventures
  332. Ingro Finanz
  333. Inno Biologics
  334. InnoMed Fund 
  335. Innovate Biopharmaceuticals
  336. Intas Pharmaceuticals
  337. Integrity Bio
  338. Intract Pharma
  339. Intrexon
  340. Ippon Capital
  341. Ipsen Pharma
  342. Ironwood Pharmaceuticals
  343. iSelect Fund
  344. Istituto Biochimico Italiano Giovanni Lorenzini
  345. Ivax Pharmaceuticals
  346. Janssen Pharmaceuticals
  347. JMP Securities Stifel
  348. Johnson & Johnson 
  349. Jordanian Pharmaceutical Manufacturing
  350. Joslin Diabetes Center
  351. Julphar 
  352. Julphar Gulf Pharmaceutical Industries
  353. Juvenile Diabetes Research Foundation (JDRF)
  354. Kafrelsheikh University
  355. Kamat Pharmatech
  356. KareBay Biochem
  357. KBI Biopharma
  358. Kemwell Biopharma
  359. KeyBioscience
  360. Kinexus Bioinformatics
  361. King Hamad University Hospital
  362. KPC Pharmaceuticals
  363. KriSan Biotech
  364. Lakeland Regional Cancer Center
  365. LAMPIRE Biological Laboratories
  366. LaunchPad Venture Group
  367. Lexicon Pharmaceuticals
  368. LFB Biomanufacturing
  369. Life Sciences Partners
  370. Lilly Ventures
  371. Lobesity
  372. LODH Immunology Fund
  373. Longevity Biotech
  374. Longitude Capital
  375. Lonza 
  376. LuinaBio
  377. Lumen Bioscience
  378. Lumira Capital
  379. Lundbeckfonden Ventures
  380. Lyfebulb
  381. Lyotex
  382. Madryn Asset Management
  383. Maine Angels 
  384. Mallinckrodt Pharmaceuticals
  385. MannKind
  386. Marathon Capital Development Fund
  387. Maruishi Pharmaceutical Company
  388. Mass Medical Angels
  389. Massachusetts General Hospital
  390. Massachusetts Institute of Technology
  391. Maverick Capital 
  392. Maxim Group
  393. Mayo Clinic
  394. McDonald Partners
  395. MD Anderson Cancer Center
  396. Medeva Pharmaceuticals
  397. Medicxi Ventures 
  398. MedImmune
  399. Medizinische Klinik - Innenstadt
  400. Medpace
  401. Menarini Biotech
  402. Mentor Pharmaceuticals
  403. Merck
  404. Meridian Life Science
  405. Merrion Pharmaceuticals 
  406. Merro Pharmaceutical
  407. MHR Fund Management
  408. MicroBiopharm Japan
  409. MidaSol Therapeutics 
  410. Midatech Pharma 
  411. MidCap Financial
  412. Millennium Pharmaceuticals
  413. Mitsubishi Tanabe Pharma
  414. Monash University
  415. Montaur Capital Partners
  416. More Investment House
  417. Morgan Stanley Investment Management
  418. MPM Capital
  419. MSD Partners
  420. MVM Life Science Partners
  421. Mylan 
  422. NanoMega Medical
  423. National Cancer Institute
  424. National Institute of Allergy and Infectious Diseases
  425. National Institute of Diabetes and Digestive and Kidney Diseases
  426. National Institutes of Health
  427. National MS Society
  428. National Multiple Sclerosis Society
  429. Neodel Pharma
  430. Neuland Laboratories
  431. New Generation Technology
  432. New River Management
  433. NewVa Capital Partners
  434. Niagara University
  435. Nitto Avecia Pharma Services
  436. Nobex 
  437. NOD Pharmaceuticals
  438. Nordic Biosciences 
  439. Nordmark Arzneimittel
  440. Norwalk Hospital
  441. Nova Laboratories
  442. Novartis 
  443. Novartis Venture Fund
  444. Novasep
  445. Novetide
  446. Novex
  447. Novimmune
  448. Novo Nordisk
  449. NSJ Prayog Life Science
  450. Nucleus Network
  451. NUMAFERM
  452. Nutrinia
  453. OctoPlus
  454. Ofer Hi-Tech Group
  455. Oklahoma Foundation for Digestive Research
  456. Olon
  457. Omnia Biologics
  458. Oragenics
  459. Oramed Pharmaceuticals
  460. Orange County Research Center
  461. OrbiMed
  462. Oregon Health & Science University
  463. Orexigen Therapeutics
  464. ORPEGEN Peptide Chemicals
  465. Oshadi Drug Administration
  466. Osmangazi University Medical School
  467. Oso Biopharmaceuticals Manufacturing
  468. OsoBio
  469. Oxalo Therapeutics
  470. Oxford Finance 
  471. P&G Pharmaceuticals
  472. Pacific Venture Opportunity Fund
  473. Panacea Biotec
  474. Paperboy Ventures
  475. Paragon Bioservices
  476. Parexel
  477. Partner Fund Management
  478. Patheon
  479. Peking University First Hospital
  480. Pendopharm
  481. Pepceuticals
  482. Pepscan
  483. Peptide Institute
  484. PeptiStar
  485. Perceptive Advisors
  486. Pfanstiehl
  487. Pfizer
  488. Pharmacia & Upjohn 
  489. Pharmstandard International
  490. piCHEM
  491. Pictet Private Equity Investors
  492. Pinemount Investments
  493. Ping An Ventures
  494. Piramal Pharma Solutions
  495. PlasmaTech Biopharmaceuticals
  496. PLIVA
  497. Polymun Scientific
  498. PolyPeptide
  499. Pontifax
  500. Praxis Pharmaceutical
  501. Precigen
  502. Precision BioSciences
  503. Premas Biotech
  504. Previtalica
  505. Priavoid
  506. PrimaPharma
  507. ProBioGen
  508. Productos Biologicos
  509. Profil Institut für Stoffwechselforschung
  510. ProJect Pharmaceutics
  511. ProMab Biotechnologies
  512. Prometheus Laboratories
  513. Protagonist Therapeutics
  514. Protalix Biotherapeutics
  515. Proteimax
  516. ProvePharm Life Solutions
  517. Psagot Investment House
  518. PureTech Health
  519. PvP Biologics
  520. PVS Memorial Hospital
  521. PX'Therapeutics
  522. PYRAMID Laboratories
  523. QIC BioVentures
  524. Qilu Hospital of Shandong University
  525. QS Pharma
  526. Quaker BioVentures
  527. Queen's University
  528. RA Capital Management
  529. Radboud University
  530. Rambam Health Care Campus
  531. Rani Therapeutics 
  532. Rebel Pharmaceuticals
  533. Reliance Life Sciences
  534. Rentschler Biopharma
  535. Rho Ventures
  536. Richter-Helm BioLogics
  537. Ridgeback Capital
  538. Riesner Verwaltungs
  539. Roche
  540. Rock Springs Capital
  541. Rosalind Capital
  542. Rosetta Capital
  543. RS Synthesis
  544. Ruijin Hospital 
  545. SAFC
  546. Saffelberg Investments
  547. Sahlgrenska University Hospital
  548. Salix Pharmaceuticals
  549. Sandoz
  550. Sanofi 
  551. Santhera Pharmaceuticals
  552. Sanyal Bio
  553. Schering-Plough
  554. Scientific Health Development Partners
  555. Scientific Protein Laboratories
  556. SciGen
  557. ScinoPharm 
  558. Seachaid Pharmaceuticals
  559. Senn Chemicals
  560. Shanghai Zhongshan Hospital
  561. Sheatree Direct
  562. Sheba Hospital
  563. Shengnuo Peptide
  564. Shenzhen JYMed Technology
  565. Shionogi 
  566. Shire
  567. Sichuang Provincial People's Hospital
  568. Sigma Capital Management
  569. Sigmoid Pharma
  570. Silicon Valley Bank
  571. Sinopep-Allsino Biopharmaceutical
  572. Slater Technology Fund
  573. Sofinnova Ventures
  574. Space Peptides
  575. Spaulding Clinical Research
  576. Sponsor
  577. Square 1 Bank
  578. SR One 
  579. SRZ Properties 
  580. St. Luke's Medical Center
  581. Stallergenes
  582. Starfish Ventures
  583. Stealth BioTherapeutics
  584. Stevanato Group
  585. Sublimity Therapeutics
  586. Sucampo Pharmaceuticals
  587. Summa Health Cancer Institute
  588. SV Health Investors
  589. Swiss Caps 
  590. Swiss Investment group
  591. Symbiosis Pharmaceutical Services
  592. SynCo Bio Partners
  593. Synergy Pharmaceuticals 
  594. Synermore Biologics 
  595. Syngene International
  596. Syntex Pharm
  597. Synthetic Biologics
  598. Takanawa Pharma
  599. Takeda
  600. Takeda Ventures
  601. Tamares Capital
  602. Tamarix Technologies Group
  603. Tapemark
  604. Tarix Pharmaceuticals 
  605. Tarsa Therapeutics
  606. TCG Lifesciences
  607. Tech Coast Angels
  608. Temasek
  609. Teva Pharmaceutical
  610. The Column Group
  611. The Halifax Group
  612. The Native Antigen Company
  613. Therapure Biopharma 
  614. Thermo Fisher Scientific
  615. Thiel Foundation
  616. Third Rock Ventures
  617. Third Security
  618. Tiziana Life Sciences
  619. TNT Pharma
  620. TPG Biotech
  621. Transgene Biotek
  622. TranXenoGen
  623. Trenzyme
  624. TriHealth
  625. TVM Capital
  626. UCB Pharma
  627. Unigene Laboratories
  628. University Hospital of Leuven
  629. University Hospital of South Manchester
  630. University of Alabama 
  631. University of Alberta
  632. University of British Columbia
  633. University of California
  634. University of Colorado
  635. University of Heidelberg
  636. University of Iowa
  637. University of Minnesota
  638. University of Montreal
  639. University of Nebraska
  640. University of Pennsylvania
  641. University of Rochester
  642. University of Southern California
  643. University of Texas
  644. University of Vienna
  645. University of Virginia
  646. University of Washington
  647. US Department of Defense
  648. US Department of Energy
  649. USV
  650. Vanderbilt-Ingram Cancer Center
  651. Varuma
  652. Venrock
  653. Ventria Bioscience
  654. VentureHealth
  655. Vertex Pharmaceuticals
  656. Vetter Pharma
  657. VHsquared
  658. Victory Park Capital 
  659. Virginia Commonwealth University
  660. Virtus Inspire Ventures
  661. Vista Biologicals
  662. VIVUS
  663. vTv Therapeutics
  664. WACKER Biotech
  665. Waisman Biomanufacturing
  666. Wake Forest University Health Sciences
  667. Washington University School of Medicine
  668. Watson Laboratories
  669. Wellington Management Company 
  670. West China Hospital
  671. West Penn Allegheny Health System
  672. WestRiver Management
  673. White Oak Global Advisors
  674. Wingate Institute of Neurogastroenterology
  675. WuXi AppTec
  676. WuXi Healthcare Ventures
  677. Wyeth Pharmaceuticals
  678. XBiotech 
  679. Xiamen Weiyang Pharmaceutical
  680. Yale Center for Clinical Investigation
  681. Yissum 
  682. Zealand Pharma
  683. Zhejiang Peptides Biotech
  684. Zhongshan Hospital 
  685. Zhongshan University
  686. Ziff Asset Management
  687. Zosano Pharma

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com